Abstract
While progress has been made in treating viral hepatitis some problems are not adequately addressed with current therapies. This includes the challenge of treating both chronic as well as fulminant infections. This chapter provides an overview about current activities in the development of novel therapies for viral hepatitis. The activities in this area are very competitive and dynamic and, therefore, the list of projects and compounds might not be complete or reflect the very latest status of certain projects. However, it is clear that the medical need is being addressed and that novel approaches can be expected that might hopefully strengthen the antiviral armamentarium in the future.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Zeuzem S, Benhamou Y, Bain VG, Shouval D, Piankos S, Flisiak R, Grigeresen M, Rehak V, Yoshida E, Kaita et al (2007) Antiviral response at week 12 following completion of treatment with albinterferon alfa-2b plus ribavirin in genotype 1, IFN-naïve, chronic hepatitis patients. 42nd Annual Meeting of the European Association for the Study of the Liver (EASL). Oral presentation. 14 April 2007
Bain VG, Maretta P, Kaita K, Yoshida E, Swain M, Bailey R, Neumann A, Grain P, McHutchinson J, Pulkstenis E, Subramanian M et al (2007) Comparable antiviral response rates with albinterferon alfa-2b dosed at Q2W or Q4W intervals in naïve subjects with genotypes 2 or 3 chronic hepatitis C. 42nd Annual Meeting of the European Association for the Study of the Liver (EASL). Oral presentation. 12 April 2007
Fiscella M, Balan V, Nelson D, Corey A (2006) Favorable pharmacokinetic of albumin interferon alfa-2b in subjects with chronic hepatitis C. 57th Annual Meeting of the American Association for the Study of Liver Diseases. 31 October 2006. Poster presentation #1140
Bain VG, Kaita KD, Yoshida EM, Swain MG, Heathcote EJ, Neumann AU, Fiscella M, Yu R, Osborn BL, Cronin PW et al (2006) A Phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis patients. J Hepatol 44: 671–678
Balan V, Nelson DR, Sulkowski MS, Everson GT, Lambiase LR, Wiegner RH, Dickson RC, Post AB, Redfield RR, Davis GL, Neumann AU et al (2006) A Phase 1/2 study evaluating escalating doses of recombinant human albumin-interferon alpha fusion protein in chronic hepatitis patients who have failed previous interferon-alpha-based therapy. Antivir Ther 11: 35–45
Depraetere S, Leroux-Roels G (1999) Hepatitis virus envelope proteins: immunogenieity in humans and their role in diagnosis and vaccine development. Viral, Hepat Rev 5: 113–146
Pockros PJ, Guyader D, Patton H, Tong MJ, Wright T, McHutchison JG, Meng (2007) Oral resiquimod in chronic HCV infection: Safety and efficacy in 2 placebo-controlled, double-blind phase Ila studies. J Hepatol 47: 174–182
Kaita (2007) Phase II study of Celgosivir in combination with peginterferon alfa-2b and ribavirin in chronic hepatitis genotype-1 non-responder patients presentation at the Digestive Disease Week, 197#x2013;24 May 2007-Washington, DC
Mealy NE, Lupone B, Tell M (2007) Drugs under development for the treatment of hepatitis. Drugs Fut 32: 191–200
Yoo Kim JH, Kim TH, Koh Um SH, Kim YS, Lee KS, Han BH, Chon CY, Han JY et al (2007) Clevudine is highly efficacious in hepatitis e antigen-negative chronic hepatitis with durable off-therapy viral suppression. Hepatology 46, 4: 1041–1046
Yoo Kim JH, Chung YH, Lee KS, Paik SW, Ryu SH, Han BH, Han JY, Byun KS, Cho M et al (2007) Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 45: 1172–1178
Flisiak R, Horban A, Kierkus J, Stanczak J, Cielniak I, Stanczak GP, Wiercinska-Drapalo A, Siwak E, Higersberger J, Aeschlimann et al (2006) The cyclophilin inhibitor DEBIO-025 has a potent dual anti-HIV and anti-HCV activity in treatment-naïve HIV/HCV co-infected subjects American Association for the Study of Liver Diseases (AASLD) Boston, 2–31 October 2006
Watashi K, Shimotolmo (2007) Chemical genetics approach to hepatitis virus replication: cyclophilin as a target for anti-hepatitis virus strategy. Rev Med Virol 17: 245–252
Stuyver LI, McBrayer TR, Thranish PM, Clark J, Hollecker L, Lostia S, Nachman T, Grier J, Bennett MA, Xie M-Y et al (2006) Inhibition of hepatills replicon RNA synthesis by ß-D-2’-deoxy-2’-fluoro-2’-methylcytidine: A specific inhibitor of hepatitis virus replication. Antiviral Chemistry and Chemotherapy 17: 79–87
Murakami E, Bao H, Ramesh M, McBrayer TR, Whitaker T, Micolochick Steuer HM, Schinazi RF, Stuyver LJ, Obikhod A, Otto MJ et al (2007) Mechanism of activation of Beta-D-2’-deoxy-2’-fluoro-2’-C-methylcytidine and inhibition of hepatitis virus NS5B RNA polymerase. Antimicrobial Agents and Chemotherapy 51(2): 503–509
Keeffe EB, Marcellin P (2007) New and emerging treatment of chronic hepatitis B. Clin Gastroenterol Hepatol 5: 285–294
Firbas Ch, Jilma B, Tauber E, Buerger V, Jelovcan S, Lingnau K, Buschle M, Frisch J, Klade Ch (2006) Immunogenicity and safety of a novel therapeutic hepatitis virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine 24: 4343–4353
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Birkhäuser Verlag Basel/Switzerland
About this chapter
Cite this chapter
Weber, O. (2008). Drug candidates for the treatment of viral hepatitis. In: Weber, O., Protzer, U. (eds) Comparative Hepatitis. Birkhäuser Advances in Infectious Diseases. Birkhäuser Basel. https://doi.org/10.1007/978-3-7643-8558-3_16
Download citation
DOI: https://doi.org/10.1007/978-3-7643-8558-3_16
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-7643-8557-6
Online ISBN: 978-3-7643-8558-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)